CVKD (Cadrenal Therapeutics) Change In Payables And Accrued Expense : $1.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics Change In Payables And Accrued Expense?

Cadrenal Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was $-0.84 Mil. It means Cadrenal Therapeutics's Accounts Payable & Accrued Expense declined by $0.84 Mil from Dec. 2024 to Mar. 2025 .

Cadrenal Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was $1.88 Mil. It means Cadrenal Therapeutics's Accounts Payable & Accrued Expense increased by $1.88 Mil from Dec. 2023 to Dec. 2024 .

Cadrenal Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Cadrenal Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics Change In Payables And Accrued Expense Chart

Cadrenal Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

-0.46

1.88

Cadrenal Therapeutics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial								0.04	0.62	-0.19	1.42	-0.84

Cadrenal Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.00 Mil.

Cadrenal Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadrenal Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082

Website

https://www.cadrenal.com

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Executives

John Raymond Murphy	director	233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham	director, 10 percent owner, officer: CEO and Chairman	89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo	officer: Chief Medical Officer	13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot	officer: Chief Financial Officer	802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson	director	2483 NE JULEP STREET, ISSAQUAH WA 98029